Home
  • E-mailTone.Bjorge@uib.no
  • Phone+47 55 58 85 30+47 995 35 990
  • Visitor Address
    Kalfarveien 31
  • Postal Address
    Postboks 7804
    5020 Bergen

Cancer epidemiology

  • Teaching at courses in epidemiology for medical and PhD students
  • Supervision of medical, PhD and postdoctoral students doing project work in epidemiology
Academic article
  • 2019. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. International Journal of Epidemiology. 93-104.
  • 2019. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 934-947.
  • 2019. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 913-933.
  • 2019. Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. International Journal of Cancer. 58-67.
  • 2019. Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. The Lancet Public Health. e658-e669.
  • 2019. BMI and weight changes and risk of obesity-related cancers: a pooled European cohort study. International Journal of Epidemiology. 1872-1885.
  • 2019. Atypical glandular lesions of the cervix and risk of cervical cancer. Acta Obstetricia et Gynecologica Scandinavica. 1-9.
  • 2019. Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study. International Journal of Cancer. 1-10.
  • 2018. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiology and Drug Safety. 995-1004.
  • 2018. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. Journal of Internal Medicine. 430-445.
  • 2018. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. International Journal of Cancer. 3071-3082.
  • 2018. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. International Journal of Cancer. 1858-1867.
  • 2018. Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study. International Journal of Cancer. 1904-1913.
  • 2018. Paternal characteristics associated with maternal periconceptional use of folic acid supplementation. BMC Pregnancy and Childbirth. 1-8.
  • 2018. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • 2018. Human papillomavirus type specific risk of progression and remission during long-term follow-up of equivocal and low-grade HPV-positive cervical smears. International Journal of Cancer. 851-860.
  • 2018. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 1859-1922.
  • 2018. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. . The Lancet. 1923-1994.
  • 2018. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 1015-1035.
  • 2018. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk. Cancer Research. 274-285.
  • 2017. Suicide and violent deaths in survivors of cancer in childhood, adolescence and young adulthood-a national cohort study. International Journal of Cancer. 575-580.
  • 2017. Preterm births and use of medication in early adulthood: a population-based registry study. Pharmacoepidemiology and Drug Safety. 742-751.
  • 2017. HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia. Gynecologic Oncology. 111-117.
  • 2017. Cohort Profile Update: The Janus Serum Bank Cohort in Norway. International Journal of Epidemiology. 1101-1102f.
  • 2016. Supplemental folic acid in pregnancy and childhood cancer risk. British Journal of Cancer. 71-75.
  • 2016. Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case–control study. British Journal of Cancer. 1416-1420.
  • 2016. Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study. British Journal of Cancer. 348-356.
  • 2016. Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men. PLOS ONE. 11 pages.
  • 2016. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • 2016. Educational attainment among long-term survivors of cancer in childhood and adolescence: a Norwegian population-based cohort study. Journal of cancer survivorship. 87-95.
  • 2016. Economic independence in survivors of cancer diagnosed at a young age: A Norwegian national cohort study. Cancer. 3873-3882.
  • 2016. Circulating folate and vitamin B12 and risk of prostate cancer: a collaborative analysis of individual participant data from six cohorts including 6875 cases and 8104 controls. European Urology. 941-951.
  • 2016. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • 2015. Supplemental folic acid in pregnancy and maternal cancer risk. Cancer Epidemiology. 805-811.
  • 2015. Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. Acta Oncologica. 200-209.
  • 2015. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology (EJE). 501-508.
  • 2015. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. International Journal of Epidemiology. 1353-1363.
  • 2015. Folic acid supplements and risk of oral clefts in the newborn: A population-based study. British Journal of Nutrition. 1456-1463.
  • 2014. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer – a large nested case-control study within the JANUS cohort in Norway. International Journal of Cancer. 197-206.
  • 2014. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology. 823-828.
  • 2014. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • 2014. Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Oncology. 1609-1615.
  • 2014. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: A prospective study of 580 000 subjects within the Me-Can project. BMC Cancer. 12 pages.
  • 2014. A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLOS ONE.
  • 2013. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. American Journal of Clinical Nutrition. 147-154.
  • 2013. Total serum cholesterol and cancer incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLOS ONE. 8 pages.
  • 2013. The Healthy Worker Effect in Cancer Incidence Studies. American Journal of Epidemiology. 1218-1224.
  • 2013. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk-a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. International Journal of Epidemiology. 201-210.
  • 2013. Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 107-116.
  • 2013. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes and Control. 151-159.
  • 2013. Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLOS ONE.
  • 2013. Increased uptake of social security benefits among long-term survivors of cancer in childhood, adolescence and young adulthood: a Norwegian population-based cohort study. British Journal of Cancer. 1525-1533.
  • 2013. HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway. Cancer Medicine. 182-189.
  • 2013. Fetal growth and childhood cancer: A population-based study. Pediatrics. E1265-E1275.
  • 2013. Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340,000 pregnancies using Norwegian population-based databases. British Journal of Clinical Pharmacology. 1134-1141.
  • 2012. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 6199-6206.
  • 2012. Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can). British Journal of Dermatology. 59-67.
  • 2012. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. International Journal of Cancer. 193-200.
  • 2012. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecologic Oncology. 330-335.
  • 2012. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Annals of Hematology. 1519-1531.
  • 2012. Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes and Control. 1297-1305.
  • 2012. Blood pressure and risk of cancer incidence and mortality in the Metabolic syndrome and cancer project. Hypertension. 802-810.
  • 2012. Blood pressure and other metabolic syndrome factors and risk of brain tumor in the large population-based Me-Can cohort study. Journal of Hypertension. 290-296.
  • 2011. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes and Control. 291-299.
  • 2011. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. European Journal of Epidemiology (EJE). 157-163.
  • 2011. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). International Journal of Cancer. 1890-1898.
  • 2011. Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can). Annals of Oncology. 1339-1345.
  • 2011. Metabolic risk factors and ovarian cancer in the Metabolic syndrome and cancer project. International Journal of Epidemiology. 1667-1677.
  • 2011. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control. 743-751.
  • 2011. Metabolic Factors and the Risk of Colorectal Cancer in 580,000 Men and Women in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer. 2398-2407.
  • 2011. Maternal birth characteristics and perinatal mortality in twin offspring. An intergenerational population-based study in Norway, 1967-2008. BJOG: an International Journal of Obstetrics and Gynaecology. 698-705.
  • 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • 2011. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety. 243-248.
  • 2011. Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiology, Biomarkers and Prevention. 1726-1735.
  • 2010. Trends in incidence and mortality for triplets in Norway 1967-2006: the influence of assisted reproductive technologies. BJOG: an International Journal of Obstetrics and Gynaecology. 667-675.
  • 2010. Metabolic syndrome and endometrial carcinoma. American Journal of Epidemiology. 892-902.
  • 2010. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiology, Biomarkers and Prevention. 1737-1745.
  • 2010. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiology, Biomarkers and Prevention. 2307-2317.
  • 2010. Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine. 335-340.
  • 2010. Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). International Journal of Epidemiology. 660-667.
  • 2009. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 1083-1089.
  • 2009. Increased risk of oesophageal adenocarcinoma among upstream petroleum workers. Occupational and Environmental Medicine.
  • 2009. Fetal down syndrome and the risk of maternal breast cancer. Epidemiology. 584-589.
  • 2009. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Medicine. 14 pages.
  • 2008. Cancer risk in children with birth defects and in their families: A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiology, Biomarkers and Prevention. 500-506.
  • 2008. Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents. American Journal of Epidemiology. 30-37.
  • 2008. Birth and parental characteristics and risk of neuroblastoma in a population-based Norwegian cohort study. British Journal of Cancer. 1165-1169.
  • 2007. Increasing twinning rates in Norway, 1967-2004: the influence of maternal age and assisted reproductive technology (ART). Acta Obstetricia et Gynecologica Scandinavica. 833-839.
  • 2007. Height and body mass index and risk of lymphohematopoietic malignancies in two million norwegian men and women. American Journal of Epidemiology. 44-52.
  • 2007. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International Journal of Cancer. 378-383.
  • 2006. The impact of height and body mass index on the risk of testicular cancer in 600,000 Norwegian men. Cancer Causes and Control. 983-987.
  • 2006. Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
  • 2005. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes and Control. 987-996.
  • 2005. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. British Journal of Cancer. 807-810.
  • 2005. Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecologic Oncology. 733-739.
  • 2004. p16(INK4a) and p21(Waf1/Cip1) expression correlates with clinical outcome in vulvar carcinomas. Gynecologic Oncology. 37-45.
  • 2004. Obesity in adolescence and adulthood and the risk of adult mortality. Epidemiology. 79-85.
  • 2004. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • 2004. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. European Journal of Cancer. 1058-1065.
  • 2004. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Analytical Chemistry. 4406-4409.
  • 2004. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. British Journal of Cancer. 1829-34.
  • 2003. Height, body mass index and prostate cancer: a follow-up of 950 000 Norwegian men. British Journal of Cancer. 1237-1242.
  • 2003. Height, body mass index and ovarian cancer: a follow-up of 1.1 million Norwegian women. Journal of the National Cancer Institute. 1244-1248.
  • 2002. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. British Journal of Cancer. 61-64.
  • 2002. Gestational trophoblastic tumors in Norway, 1968-1997: Patient characteristics, treatment and prognosis. Gynecologic Oncology. 71-76.
  • 2002. Bruk av p-piller og risiko for kreft. Tidsskrift for Den norske legeforening. 1788-1790.
  • 2001. kan testing og vaksinering for humant papillomavirus forebygge livmorhalskreft. Tidsskrift for Den norske legeforening. 2947-2951.
  • 2001. Kan testing og vaksinering av humant papillomavirus forebygge livmorhalskreft? Tidsskrift for Den norske legeforening. 2947-51.
  • 2000. Ovarialcancerscreening. Tidsskrift for Den norske legeforening. 1440-1448.
  • 2000. Chlamydia trachomatis infection as a risk factor for invasive cervical carcinoma. International Journal of Cancer. 35-39.
  • 2000. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International Journal of Cancer. 35-39.
  • 1999. Screening mot kreft. Tidsskrift for Den norske legeforening. 1129-1136.
  • 1999. No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. International Journal of Cancer. 818-22.
  • 1998. Prognosis of patients with Ovarian Cancer and Borderline Tumours Diagnosed in Norway between 1954 and 1993. International Journal of Cancer. 663-670.
  • 1998. Prognosis of 2.800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstetricia et Gynecologica Scandinavica. 777-781.
  • 1998. Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • 1998. Ovarialcancer og borderlinetumorer. Tidsskrift for Den norske legeforening. 2471-2475.
  • 1997. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-93. Acta Obstetricia et Gynecologica Scandinavica. 606.
  • 1997. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. International Journal of Cancer. 780-786.
  • 1997. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ. British Medical Journal. 646-649.
  • 1997. Prospective seroepidemiologic study of human papilloma virus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute. 1293-1299.
  • 1997. Prognosis of 3,000 Patients with Epithelial Ovarian Cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Society of Pelvic Surgeons: Forty-seventh annual meeting. 35.
  • 1997. Ovarian Cancer-Are we making progress? European Journal of Cancer. 621.
  • 1997. Hormonell substitusjonsbehandling og kreft. Tidsskrift for Den norske legeforening. 2201-2207.
  • 1997. A Prospective, Seroepidemiological Study of the Role of Human Papillomavirus in Esophageal Cancer in Norway. Cancer Research. 3989-3992.
  • 1996. Reproductive variables and risk of uterine cervical cancer in Norwegian registry data. Cancer Causes and Control. 351-357.
  • 1996. Reproductive factors and prognosis of uterine cervical cancer in Norway. British Journal of Cancer. 1843-1846.
Report
  • 2012. Årstabeller for Medisinsk fødselsregister 2010 Fødsler i Norge. 2012. 2012. .
  • 2011. Årstabeller for Medisinsk fødselsregister 2009. Fødsler i Norge. 2011. 2011. .
  • 2011. Årsrapport for Medisinsk fødselsregister 2009. Fødsler i Norge. 2009. 2009. .
  • 2011. Sekundærscreening med HPV-tester i Masseundersøkelsen mot livmorhalskreft. .
  • 2002. Trofoblast tumorer i Norge 1968-97. Pasientkarakteristika, behandling og prognose. .
Academic lecture
  • 2007. Medfødte misdannelser og kreft, felles årsaksbakgrunn?
  • 2000. The joint effects of sexually transmitted infections on the risk of cervical cancer.
Reader opinion piece
  • 2006. Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. Histopathology. 311-312.
Short communication
  • 2005. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. British Journal of Cancer. 807-810.
Popular scientific article
  • 2012. HPV-evalueringen – så rettferdig som mulig. Dagens medisin.
  • 2011. HPV-evalueringen: Ingen særbehandling av enkelttester. Dagens medisin.
  • 2011. HPV-evaluering: Ekstra celleprøve kompenserer ikke for lav sensitivitet på den norske testen. Dagens medisin.
Feature article
  • 2010. Parodisk personvern. Dagbladet.
Letter to the editor
  • 2006. Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. Histopathology. 311-312.
Doctoral dissertation
  • 2019. Folic acid in pregnancy and subsequent cancer risk in mothers and their children: An epidemiologic study in Norway, 1999–2010.
Academic chapter/article/Conference paper
  • 2011. Special Issue: Cancer Screening in Norway, 2011. 12 pages.
Abstract
  • 2012. Metabolic syndrome and cervical cancer in the Metabolic Syndrome and Cancer Project (Me-Can). Journal of Women's Health. 39-39.
  • 2011. The Strength of the Healthy Worker Effect Varies According to the Type of Cancer Being Studied. Epidemiology. S261-S262.
  • 2011. TOTAL SERUM CHOLESTEROL AND CANCER INCIDENCE IN THE METABOLIC SYNDROME AND CANCER PROJECT (ME-CAN). Journal of Epidemiology and Community Health. A302-A302.
  • 2011. METABOLIC SYNDROME AND RISK OF BRAIN TUMOUR IN A LARGE POPULATION-BASED COHORT STUDY. Journal of Epidemiology and Community Health. A238-A239.
  • 2011. METABOLIC SYNDROME AND CERVICAL CANCER IN THE METABOLIC SYNDROME AND CANCER PROJECT (ME-CAN). Journal of Epidemiology and Community Health. A279-A279.
  • 2007. Twinning and triplet rates in Norway, 1967-2004. Human Reproduction. S30.
Errata
  • 2013. Erratum to: Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway. Cancer Causes and Control. 2253-2256.
  • 2004. Corrigendum. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. British Journal of Cancer. 1226.

More information in national current research information system (CRIStin)

 

20 selected publikations:

 

1.Bjørge T, Dillner J, Anttila T, Engeland A, Hakulinen T, Jellum E, Lehtinen M, Luostarinen T, Paavonen J, Pukkala E, Sapp M, Schiller J, Youngman L, Thoresen S. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997; 315: 646-9.

 

2.Bjørge T, Hakulinen T, Engeland A, Jellum E, Koskela P, Lehtinen M, Luostarinen T, Paavonen J, Sapp M, Schiller J, Thoresen S, Wang Z, Youngman L, Dillner J. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res 1997; 57: 3989-92.

 

3. Dillner J, Lehtinen M, Bjørge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller J, Hakulinen T, Thoresen S, Hakama M. A prospective, seroepidemiological study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997; 89: 1293-9.

 

4. Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998; 75: 663-70.

 

5. Engeland A, Tretli S, Bjørge T. Height, body mass index, and ovarian cancer - a follow-up of 1,1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-8.

 

6. Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004; 91: 1829-34.

 

7.Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 2004; 160: 1168-76.

 

8. Bjørge T, Engeland A, Tretli, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007; 120: 378-83.

 

9. Engeland A, Tretli S, Hansen S, Bjørge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol 2007; 165: 44-52.

 

10. Bjørge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer risk in families of children with birth defects. A population based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev 2008; 17: 500-6.

 

11. Bjørge T, Engeland A, Tverdal A, Davey Smith G. Body mass index in adolescence in relation to cause-specific mortality: A follow-up of 230,000 Norwegian adolescents. Am J Epidemiol 2008; 168: 30-7.

 

12. Bjørge T, Cnattingius S, Engeland A, Tretli S, Lie RT, Lukanova A. Fetal Down syndrome and the risk of maternal breast cancer. Epidemiology 2009; 20; 584-9.

 

13. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P. Blood glucose and risk of incident and fatal cancer in the Metabolic syndrome and Cancer project (Me-Can): Analysis of six prospective cohorts. PLoS Med 2009; 6 (12): e1000201. DOI:10.1371/journal.pmed.1000201.

 

14. Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Concin H, Hallmans G, Jonsson H, Stattin P, Engeland A. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010; 171: 892-902.

 

15. Bjørge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Häggström C, Stattin P, Engeland A. Metabolic syndrome and breast cancer in the Me-Can (Metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010; 19: 1737-45.

 

16. Bjørge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Jonsson H, Häggström C, Stattin P, Engeland A. Metabolic syndrome and ovarian cancer in the Me-Can (Metabolic syndrome and cancer) project. Int J Epidemiol 2011; 40: 1667-77.

 

17. Ghaderi S, Engeland A, Moster D, Ruud E, Syse A, Wesenberg F, Bjørge T. Increased uptake of social security benefits among long-term survivors of cancer in childhood, adolescence and young adulthood: A Norwegian population-based cohort study. Br J Cancer 2013; 108: 1525-33.

 

18. de Vogel S, Meyer K, Fredriksen Å, Ulvik A, Ueland PM, Nygård O, Vollset SE, Tell GS, Tretli S, Bjørge T. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk. Int J Epidemiol 2013; 42: 201-10.

 

19. de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygård O, Vollset SE, Tell GS, Gregory JF, Tretli S, Bjørge T. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer – a large nested case-control study within the JANUS cohort in Norway. Int J Cancer 2014; 134: 197-206.

 

20. Bjørge T, Sørensen HT, Grotmol T, Engeland A, Stephansson O, Gissler M, Tretli S, Troisi R. Fetal growth and childhood cancer: A population-based study. Pediatrics 2013; 132: e1265-75.

 

MD, consultant pathologist

PhD in cancer epidemiology

  • Cancer risk in families of children with birth defects: Cohort study of cancer risk among all individuals with birth defects in Norway and Sweden and their parents and siblings
  • Birth characteristics in relation to cancer among children and adolescents: Population-based Norwegian cohort study, with data from the medical birth and cancer registries of Norway
  • Metabolic syndrome and cancer (Me-Can): Population-based cohort study (with participating cohorts from Norway, Sweden and Austria) of the relation between factors in the metabolic syndrome and cancer risk
  • Folate metabolism and cancer: Evaluation of the relation between serum folate, other B-vitamins, metabolites, biomarkers and polymorphisms in genes (SNPs) involved in the folate metabolism and cancer risk. The study is based on data from the Hordaland Homocysteine and Health Studies and the Janus Serum Bank
  • Supplemental folic acid in pregnancy and later health consequences for the mother and the child
  • Long-term consequences of cancer in childhood and adolescence: Registry-based national cohort study of later medical and social disabilities in individuals diagnosed with cancer in childhood and adolescence (below 25 years of age)
Fields of competence 

Research groups